fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1984-1990

  Dudhani, Rajesh V ^a   Turnidge, John D ^b,c   Nation, Roger L ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Emergence of resistance; Gram negative bacteria; Heteroresistance; Population analysis profiles

Indexed keywords

COLISTIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; FEMALE; IN VIVO STUDY; LUNG INFECTION; MOUSE; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PREDICTION; THIGH; THIGH INFECTION;

EID: 77955637263     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq226     Document Type: Article

References (26)

1. Talbot GH, Bradley J, Edwards JE Jr et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 1271-81.
4. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
5. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2010. Clinical Breakpoint Tables for Interpretation of MICs and Zone Diameters (Version 1.1 April 2010). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.1.pdf (07 May 2010, date last accessed).
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 17th Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
7. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-50.
8. Yau W, Owen RJ, Poudyal A et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infection 2009; 58: 138-44.
9. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52: 351-2.
10. Li J, Milne RW, Nation RL et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-70.
11. Dudhani RV, Turnidge JD, Coulthard K et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54: 1117-24.
12. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-40.
13. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-92.
14. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-5.
15. Owen RJ, Li J, Nation RL et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-7.
16. Tan C-H, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-5.
17. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
18. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-51.
19. Reed MD, Stern RC, O'Riordan MA et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41: 645-54.
20. Dudhani RV, Li J, Nation RL. Plasma binding of colistin involves multiple proteins and is concentration dependent: potential clinical implications. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-576, p. 41. American Society for Microbiology, Washington, DC, USA.
21. Morita K, Yamaji A. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum a 1-acid glycoprotein levels. Ther Drug Monit 1995; 17: 107-12.
22. Voulgari F, Cummins P, Gardecki TI et al. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J 1982; 48: 352-6.
23. British Society for Antimicrobial Chemotherapy. BSAC Methods for Antimicrobial Susceptibility Testing, Version 8 [online]. http://www.bsac.org.uk/_db/_documents/Version_8_-_January_2009.pdf (07 May 2010, date last accessed).
24. David MD, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother 2008; 61: 962-4.
25. Li J, Nation RL, Owen RJ et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45: 594-8.
26. Mendes RE, Fritsche TR, Sader HS et al. Increased antimicrobial susceptibility profiles among polymyxin resistant Acinetobacter baumannii clinical isolates. Clin Infect Dis 2008; 46: 1324-6.